Bristol Myers Squibb and Disability Solutions have together devised ‘Dubbed Disability Diversity in Clinical Trials’. This is an initiative that aims to make recommendations regarding ways through which engagement of disabled participants in the clinical trials can be ensured. This programme will improve engagement, speed of enrolment, and help disabled individuals access clinical trials. Bristol Myers Squibb’s Disability Advancement Workplace Network (DAWN) and the Global Drug Development Team will lead DDiCT initiative. The lead, Tinamarie Duff, said that it is essential to broaden the scope of medical trials and diversify it as disabled individuals make up one of the biggest underrepresented group. While efforts to increase inclusivity are being made, Bristol Myers Squibb is all set to put their share of endeavours.
Read More from EuropeanPharmaceuticalReview
